Cellceutix Poster Presented At American Association for Cancer Research; Dr. Menon Selected for Expert Panel
Stuart Smith (October 13th, 2009) Writes:
Cellceutix of Beverly, MA, to Pursue Development for Drug-Resistant Lung Cancer
BEVERLY, Mass., Oct. 13, 2009 (GLOBE NEWSWIRE) — Cellceutix Corporation (OTCBB:CTIX) today announced that it presented a poster and its Chief Scientific Officer, Dr. Krishna Menon, was one of only four individuals selected to participate in an expert panel discussion of the abstract at the American Association for Cancer Research (AACR) meeting “Frontiers in Basic Cancer Research” in Boston, MA on October 10, 2009. The Company’s poster describes in vitro and in vivo research on its lead compound, Kevetrin(TM), which is being developed for drug resistant cancers. The three day AACR meeting featured presentations on the latest advances in basic cancer research from around the world. The AACR issued a press release on October 10, 2009 which featured the abstract submitted
...American Association for Cancer Research;, anti-inflammatory drug developer, Boston, Breast Cancer, cancer, Cancer Research, Cancers, Cellceutix Corporation, chief scientific officer, Colon Cancer, Investing Lessons, Krishna Menon;, Lung Cancer, Massachusetts, Paclitaxel, psoriasis, Small & Micro Cap, smallcapvoice, treatment for certain cancers, treatment of psoriasis, tumor, www.cellceutix.com


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)

